ESMO Congress 2024 | OncologyPRO

Abstract 1675P

Background

Adjuvant hormonal therapy (AHT) is integral to breast cancer management but often severely impacts the quality of life (QoL), especially concerning sexual functioning and psychological well-being. This study evaluates the effects of AHT on the sexual and global QoL of young breast cancer survivors.

Methods

This cross-sectional study was conducted at two cancer centers within Cairo, Egypt, involving 644 young breast cancer patients. The European Organization for Research and Treatment of Cancer EORTC QLQ - BR45 questionnaire was employed to assess the impact of AHT on sexual and global QoL. Data analysis encompassed demographic factors, treatment regimens, duration of therapy, functional and symptomatic scales of the questionnaire.

Results

The participants' median age was 41 years (range: 25-45), the primary AHT consisted of Tamoxifen + LHRH analogues (55.4%). there was a notable decrease in sexual enjoyment, with 50.7% of participants reporting no sexual activity in the past month. Among those who were sexually active, only 7.1% reported high enjoyment post-treatment compared to 31.5% pre-treatment. Additionally, 48.1% of patients experienced a complete lack of sexual desire post-treatment, while 38% expressed a significant need for psychological support. Analysis of the EORTC QLQ - BR45 questionnaire revealed Sexual Enjoyment Score: 52.9, Body image score 59.3, and Endocrine side effect score 49.4.

Conclusions

The findings reveal a profound impact of AHT on both the sexual and overall QoL among young breast cancer patients. The significant decline in sexual enjoyment and desire, coupled with a substantial need for psychological support, underscores the necessity for integrated care strategies that address the comprehensive health challenges faced by young breast cancer survivors.